A detailed history of China Universal Asset Management Co., Ltd. transactions in Alkermes Plc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 31,671 shares of ALKS stock, worth $872,536. This represents 0.1% of its overall portfolio holdings.

Number of Shares
31,671
Previous 19,882 59.29%
Holding current value
$872,536
Previous $479,000 84.97%
% of portfolio
0.1%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$23.01 - $28.55 $271,264 - $336,575
11,789 Added 59.29%
31,671 $886,000
Q2 2024

Jul 19, 2024

SELL
$23.21 - $27.24 $283,811 - $333,090
-12,228 Reduced 38.08%
19,882 $479,000
Q1 2024

Apr 29, 2024

BUY
$26.4 - $32.56 $338,025 - $416,898
12,804 Added 66.32%
32,110 $869,000
Q4 2023

May 21, 2024

SELL
$23.37 - $28.68 $299,229 - $367,218
-12,804 Reduced 39.88%
19,306 $535,000
Q4 2023

Jan 23, 2024

BUY
$23.37 - $28.68 $351,367 - $431,203
15,035 Added 352.03%
19,306 $536,000
Q3 2023

May 21, 2024

BUY
$27.17 - $31.97 $56,893 - $66,945
2,094 Added 96.19%
4,271 $119,000
Q3 2023

Oct 30, 2023

BUY
$27.17 - $31.97 $56,893 - $66,945
2,094 Added 96.19%
4,271 $120,000
Q2 2023

May 21, 2024

SELL
$28.34 - $33.63 $1,417 - $1,681
-50 Reduced 2.25%
2,177 $68,000
Q2 2023

Jul 27, 2023

SELL
$28.34 - $33.63 $1,417 - $1,681
-50 Reduced 2.25%
2,177 $68,000
Q1 2023

May 21, 2024

BUY
$25.31 - $29.02 $14,122 - $16,193
558 Added 33.43%
2,227 $62,000
Q1 2023

Apr 27, 2023

BUY
$25.31 - $29.02 $14,122 - $16,193
558 Added 33.43%
2,227 $63,000
Q4 2022

May 21, 2024

SELL
$21.94 - $26.24 $667,875 - $798,771
-30,441 Reduced 94.8%
1,669 $43,000
Q4 2022

Jan 31, 2023

BUY
$21.94 - $26.24 $2,874 - $3,437
131 Added 8.52%
1,669 $44,000
Q3 2022

Oct 21, 2022

BUY
$22.0 - $31.87 $33,836 - $49,016
1,538 New
1,538 $34,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.53B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.